Michael Shusterman
Overview
Explore the profile of Michael Shusterman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang X, Lan R, Liu Y, Pillarisetty V, Li D, Zhao C, et al.
NPJ Precis Oncol
. 2025 Mar;
9(1):58.
PMID: 40032924
Neoadjuvant therapy (NAT) is increasingly being used for pancreatic ductal adenocarcinoma (PDAC). This study investigates how NAT differentially impacts PDAC's carcinoma cells and the tumor microenvironment (TME). Spatial transcriptomics was...
2.
Peng C, Saffo S, Oberstein P, Shusterman M, Thomas C, Becker D, et al.
J Natl Compr Canc Netw
. 2024 Sep;
22(8):521-527.
PMID: 39236754
Background: 5-Fluorouracil (5-FU) is a major component of gastrointestinal cancer treatments. In multidrug regimens such as FOLFOX, FOLFIRI, and FOLFIRINOX, 5-FU is commonly administered as a bolus followed by an...
3.
Hissong E, Bhinder B, Kim J, Ohara K, Ravichandran H, Al Assaad M, et al.
Res Sq
. 2024 Aug;
PMID: 39108491
Colorectal carcinoma (CRC) is a heterogeneous group of tumors with varying therapeutic response and prognosis, and evidence suggests the tumor immune microenvironment (TIME) plays a pivotal role. Using advanced molecular...
4.
Zhang X, Lan R, Liu Y, Pillarisetty V, Li D, Zhao C, et al.
Res Sq
. 2024 May;
PMID: 38798691
Background: Neoadjuvant therapy (NAT) is increasingly being used for pancreatic ductal adenocarcinoma (PDAC) treatment. However, its specific effects on carcinoma cells and the tumor microenvironment (TME) are not fully understood....
5.
Alnajar H, Ravichandran H, Rendeiro A, Ohara K, Al Zoughbi W, Manohar J, et al.
Cold Spring Harb Mol Case Stud
. 2022 Apr;
8(3).
PMID: 35483877
Sarcomatoid urothelial carcinoma (SUC) is a rare subtype of urothelial carcinoma (UC) that typically presents at an advanced stage compared to more common variants of UC. Locally advanced and metastatic...
6.
Wong K, Shusterman M, Goel S, Negassa A, Lin J, Gartrell B
Clin Genitourin Cancer
. 2021 Feb;
19(3):e166-e170.
PMID: 33602582
Background: Non-Hispanic blacks (NHB) with renal cell carcinoma (RCC) are more likely to have papillary RCC (pRCC) than non-Hispanic whites (NHW). Data on histologic subtypes in RCC in Hispanics (H)...
7.
Brar G, Pinheiro L, Shusterman M, Swed B, Reshetnyak E, Soroka O, et al.
J Clin Oncol
. 2020 Sep;
38(33):3914-3924.
PMID: 32986528
Purpose: SARS-CoV-2 (COVID-19) is a systemic infection. Patients with cancer are immunocompromised and may be vulnerable to COVID-related morbidity and mortality. The objectives of this study were to determine if...
8.
Foronda M, Tarumoto Y, Schatoff E, Leach B, Diaz B, Zimmerman J, et al.
PLoS One
. 2020 Jan;
14(12):e0226645.
PMID: 31891587
Tankyrase (TNKS) 1/2 are positive regulators of WNT signaling by controlling the activity of the ß-catenin destruction complex. TNKS inhibitors provide an opportunity to suppress hyperactive WNT signaling in tumors,...
9.
Shusterman M, Jou E, Kaubisch A, Chuy J, Rajdev L, Aparo S, et al.
J Gastrointest Cancer
. 2019 Nov;
51(3):868-876.
PMID: 31677056
Purpose: The neutrophil-to-lymphocyte ratio (NLR) is associated with decreased overall survival in patients with pancreatic adenocarcinoma (PAC) in studies including few minority patients. We investigated the association between NLR and...
10.
Shusterman M, Grassl N, Berger K, De Sancho M
J Thromb Thrombolysis
. 2019 Aug;
49(1):153-158.
PMID: 31456167
Primary brain tumors, both benign and malignant, pose a high risk of perioperative venous thromboembolism (VTE) due to the development of a prothrombotic state. Perioperative pharmacologic thromboprophylaxis with subcutaneous (SC)...